Sveriges Riksbank
USD TENDER OPERATION ANNOUNCEMENT
Bid date, 2021-01-07 | |
Bid Date | 2021-01-07 |
Bid times | 14.00-14.30 (CET/CEST) on the Bid date |
Offerent Amount | USD 10 billion |
Maximum Permitted Volume of Bids | USD 4 billion from an individual institution |
Settlement Date | 2021-01-11 |
Minimum Permitted Bid Volume | 100 USD million per bid |
Maximum Allocation | 40 per cent of the Offerend amount |
Allocation time | No later than 15.00 (CET/CEST) on the Bid date |
Maturity Date | 2021-04-01 |
Maximum Number of Bids | 10 per individual institution |
Minimum Bid Rate | 0.33 percentage points |
Confirmation of bids to e-mail | eol@riksbank.se |
Stockholm, 2021-01-07
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Synairgen plc25.1.2021 08:06:49 CET | Press release
Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients
F. Hoffmann-La Roche Ltd25.1.2021 08:06:08 CET | Press release
Roche renews partnership with Sysmex to deliver haematology testing solutions
Royal Philips25.1.2021 08:06:08 CET | Press release
Philips delivers Q4 sales of EUR 6.0 billion, with 7% comp. sales growth; income from cont. operations increases to EUR 608 million, Adjusted EBITA margin improves 110 bps to 19.0%, and operating cash flow increases to EUR 1,305 million
F. Hoffmann-La Roche Ltd25.1.2021 08:02:27 CET | Press release
Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration
Junshi Biosciences25.1.2021 08:01:47 CET | Press release
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
Montreal Heart Institute23.1.2021 07:02:08 CET | Press release
Colchicine reduces the risk of COVID-19-related complications
Zealand Pharma22.1.2021 22:06:25 CET | Press release
Zealand Pharma announces update to 2020 financial guidance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom